<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03324477</url>
  </required_header>
  <id_info>
    <org_study_id>11-2017</org_study_id>
    <nct_id>NCT03324477</nct_id>
  </id_info>
  <brief_title>The Hemodynamic Effects of Hypertonic Saline Preload Versus Coload Measured by Non-invasive Cardiometry in Patients Undergoing TURP Surgery</brief_title>
  <official_title>Cardiometrically Evaluated NaCl 3% Coload Versus Preload for TURP. A Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nazmy Edward Seif</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to investigate the relevance of the timing of hypertonic saline&#xD;
      administration either as a preload or as a coload on hemodynamic parameters in patients&#xD;
      undergoing TURP surgeries.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Benign prostatic hyperplasia is common in elderly males, and this group of patients is&#xD;
      commonly associated with different comorbidities especially of the cardiovascular system ,&#xD;
      this make them at risk of many intraoperative complications. The associated adverse effects&#xD;
      arising in both the cardiovascular and nervous systems are known as transurethral resection&#xD;
      (TUR) syndrome.Therefore TURP patients need meticulous monitoring of hemodynamics and fluid&#xD;
      therapy.&#xD;
&#xD;
      This study is designed to investigate the relevance of the timing of hypertonic saline&#xD;
      administration either as a preload or as a coload on hemodynamic parameters in patients&#xD;
      undergoing TURP surgeries.&#xD;
&#xD;
      100 ASA physical status I-III male patients scheduled to electively undergo transurethral&#xD;
      resection of the prostate under spinal subarachnoid block were included in this study&#xD;
&#xD;
      Preload group (Group P):&#xD;
&#xD;
      50 Patients will receive 4 ml/kg of hypertonic saline (NaCL3%) via G14 cannula over 15-20 min&#xD;
      before the induction of spinal anaesthesia.&#xD;
&#xD;
      Co-load group (Group C):&#xD;
&#xD;
      50 Patients will receive 4 ml/kg of hypertonic saline (NaCL3%) via G14 cannula at the maximal&#xD;
      possible rate at the time of identification of C.S.F .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>systolic blood pressure</measure>
    <time_frame>two hours</time_frame>
    <description>systolic blood pressure is measured by mmHg</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Transurethral Resection of Prostate Syndrome</condition>
  <arm_group>
    <arm_group_label>preload group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 4 ml/kg of hypertonic saline 3% via G14 cannula over 15-20 min before the induction of spinal anaesthesia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>coload group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 4 ml/kg of hypertonic saline 3% via G14cannula at the maximal possible rate at the time of identification of C.S.F .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hypertonic saline 3%</intervention_name>
    <description>hypertonic saline 3% is a type of crystalloid solutions with osmolarity higher than that of plasma</description>
    <arm_group_label>coload group</arm_group_label>
    <arm_group_label>preload group</arm_group_label>
    <other_name>hypertonic saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  American Society of Anesthesiologists (ASA) physical status I - III.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient refusal.&#xD;
&#xD;
          -  Patient in whom spinal anesthesia is absolutely contraindicated.&#xD;
&#xD;
          -  Known sensitivity to local anesthetics.&#xD;
&#xD;
          -  Preoperative electrolyte imbalance.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nazmy E Seif, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manal M Elgohary, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manar M Elkholy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of Medicine, Cairo University</name>
      <address>
        <city>Cairo</city>
        <zip>11562</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 22, 2017</study_first_submitted>
  <study_first_submitted_qc>October 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2017</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Nazmy Edward Seif</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

